ClinicalTrials.gg
Drug

Zolbetuximab clinical trials

Also written IMAB362 and Vyloy.

studies test it
17
open now
7
in phase 3
3
first study started
2009

How each study uses zolbetuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the zolbetuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Oct 2024 · VYLOY · BLA 761365 (FDA, Drugs@FDA)
European Union
19 Sept 2024 · Vyloy · EMEA/H/C/005868 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

zolbetuximab
15

Brand

Vyloy
2

Development codes

IMAB362
11

Other names

Claudiximab
1

Studies by the year they started

17 studies that test it; most in 2018 (4)

Studies that test zolbetuximab, by start year
YearStudies
20091
20101
20121
20184
20192
20254
20264

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
9
Phase 3
3
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 5

Astellas Pharma Global Development, Inc. (8) · Ganymed Pharmaceuticals GmbH (2) · Astellas Pharma Inc (1) · Astellas Pharma China, Inc. (1) · Midhun Malla (1) · National Cancer Center, Japan (1) · American Association for Cancer Research (1) · Universitaire Ziekenhuizen KU Leuven (1)

Often tested with

Tested in the same studies.

Modified FOLFIRINOX Regimen (1) · Modified FOLFOX6 Regimen (1) · CAPOX Regimen (1) · Durvalumab (1) · Zanidatamab (1) · Oxaliplatin (1) · Docetaxel (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Zolbetuximab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 2

Studies that test zolbetuximab.

Studies

Open first, then newest update. How each study uses zolbetuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 4 — zolbetuximab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with zolbetuximab

Codes

What other systems call zolbetuximab · ClinicalTrials.gg INT006409

  • MeSH (NLM) C585662zolbetuximabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) TF5MPQ8WGYZOLBETUXIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q17107865zolbetuximabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C85475ZolbetuximabOne source FDA
  • DrugBank DB15118One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.